Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A for At-Level Back Pain in SCI
NCT02736890Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2016
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in neuropathic pain comparing Botulinum Toxin A with Placebo (2 arms). Primary endpoint: Numeric Pain Rating Scale at 24 weeks. Started Mar 2016; status: terminated.
02
Drugs
Onabotulinumtoxina + hydrogel
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT02736890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736890.